Full-Time
Senior Research Site Partnership Manager
Updated on 8/1/2026
Sarah Cannon Research Institute (SCRI)
1-10 employees
Community-based oncology clinical research organization
No salary listed
Tennessee, USA
Remote
 Biology & Biotech (1) |
|---|
Get referred to Sarah Cannon Research Institute (SCRI)
See people who can refer or advise you
- A bachelor's degree is required.
- Experience supporting oncology research sites and clinical trial enrollment is required.
- Experience in site engagement, account management, or clinical operations is required.
- Knowledge of clinical research operations and site-level execution is required.
- Understanding of oncology clinical trials and enrollment drivers is required.
- Familiarity with performance metrics and site engagement strategies is required.
- Relationship management and stakeholder engagement skills are required.
- Data interpretation and performance monitoring skills are required.
- Communication and facilitation across cross-functional teams are required.
- Problem-solving and issue resolution skills are required.
- The ability to operate effectively in a matrixed environment is required.
- The ability to manage multiple site relationships simultaneously is required.
- The ability to influence without direct authority is required.
- The ability to translate strategic priorities into site-level execution is required.
- Serve as a primary relationship manager for a portfolio of oncology research sites.
- Support site engagement, alignment, and performance with a focus on clinical trial enrollment growth.
- Execute strategic account plans and bring forward site-level insights.
- Partner with site leaders to address challenges and support operational success.
- Collaborate across teams to implement enterprise initiatives.
- Manage a portfolio of approximately 2–4 oncology research sites, depending on complexity.
- Maintain an understanding of each site’s structure, goals, and opportunities.
- Support alignment of enterprise initiatives with site needs.
- Support accountability for clinical trial enrollment performance.
- Monitor enrollment trends and identify improvement opportunities.
- Assist in development and tracking of site-level action plans.
- Promote best practices that support accrual.
- Partner with sites to review, track, and report key performance indicators and support performance improvement efforts.
- Support implementation of enterprise priorities at the site level.
- Assist sites through change initiatives and workflow transitions.
- Escalate trends, risks, and opportunities to leadership.
- Identify and support resolution of operational challenges at the site level.
- Escalate complex or high-impact issues appropriately.
- Identify opportunities to improve processes and engagement.
- A master's degree is preferred.
Sarah Cannon Research Institute (SCRI) is a global oncology research organization that conducts cancer clinical trials in community settings, partnering with pharmaceutical and biotech sponsors, physicians, and patients to develop new treatments. It works as an oncology-focused contract research organization (CRO) and centralized site management organization (SMO), running trials across more than 200 locations with roughly 1,500 research physicians, and applies technology such as its Accelero platform to personalized-medicine studies. Over more than 30 years it has completed more than 900 first-in-human trials across early- to late-phase research. What sets SCRI apart is this community-based model paired with early-phase depth, which has helped advance most new cancer therapies the FDA approved in the past decade. The goal is to accelerate oncology research from early trials to approval and bring advanced cancer treatments to patients.
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
Beach Haven, New Jersey
Founded
N/A
Get referred to Sarah Cannon Research Institute (SCRI)
See people who can refer or advise you
Simplify's Take
What believers are saying
- Pfizer collaboration expands high-value sponsor work across SCRI's community oncology network.
- SCRI's scale improves patient access and speeds feasibility across multiple tumor types.
- Heavy ASH 2025 output signals strong scientific productivity and investigator engagement.
What critics are saying
- Pfizer dependence concentrates revenue and pipeline exposure in one major sponsor.
- Execution misses on Accelero would damage SCRI's speed claims and sponsor trust.
- Large multi-site network increases quality-control and compliance risk across locations.
What makes Sarah Cannon Research Institute (SCRI) unique
- Accelero cut study activation timelines 47% and first-patient enrollment 57%.
- SCRI combines roughly 1,500 physicians across 200-plus community trial sites.
- SCRI uses real-world data to guide Pfizer oncology study design and execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Company News
Why research matters at Colorado Blood Cancer Institute. At Colorado Blood Cancer Institute, research is more than discovery. It is part of how care moves forward. Through its collaboration with Sarah Cannon Research Institute, CBCI is helping connect patients to emerging therapies, advance early-phase blood cancer research and contribute to national conversations shaping the future of oncology care. May 14, 2026 At Colorado Blood Cancer Institute (CBCI), research is woven into patient care. It shapes how care is delivered, opens doors to new possibilities and helps move progress forward for every patient who walks through its doors. That matters deeply in blood cancer care, where treatment is evolving at a remarkable pace. New therapies, new combinations and new approaches are steadily expanding what may be possible for patients. In that environment, research is not only about discovery. It is also about access, helping connect patients to emerging options while shaping the future of cancer care. At Colorado Blood Cancer Institute, that work is supported through an embedded research infrastructure in collaboration with Sarah Cannon Research Institute (SCRI). Kelly Mozzetta, regional director of oncology research operations for CBCI and Sarah Cannon Research Institute at HCA HealthONE, a phase I drug development unit, describes a model in which regulatory specialists, coordinators, nurses, lab teams and physicians work closely together to bring clinical trials to patients in the Rocky Mountain region. Rather than operating separately, the research team is integrated into the day-to-day life of the organization and works together to support patients throughout their care journey. That level of integration matters for patients. Clinical trials can offer access to therapies that may not otherwise be available, particularly for patients whose disease has relapsed or who have exhausted standard FDA-approved treatment options. Just as important is the level of physician engagement. Mozzetta emphasizes that research involvement at Colorado Blood Cancer Institute is not limited to a small subset of providers. Instead, she describes strong engagement across the physician group, along with active work in complex and emerging areas such as early-phase blood cancer research and cellular therapy. Joshua Gordon, manager of study operations at Sarah Cannon Research Institute at HCA HealthONE, adds that Colorado Blood Cancer Institute is a leader in early-phase blood cancer research and consistently ranks among the highest-enrolling practices within the field. The recent selection of an abstract by Dr. Peter Forsberg for presentation at the 2026 American Society of Clinical Oncology (ASCO), Annual Meeting, the largest oncology conference in the world, offers one example of that culture in action. ASCO is one of the most prominent conferences in cancer care, making abstract selection a meaningful marker of scientific contribution and national visibility. More broadly, it reflects the caliber of work taking place at Colorado Blood Cancer Institute and its role in larger conversations shaping oncology care. The larger takeaway is clear: research is how cancer care advances. At Colorado Blood Cancer Institute in collaboration with Sarah Cannon Research Institute, that work is carried forward through scientific rigor, physician engagement and a shared commitment to expanding what is possible for patients. Published: May 13, 2026 May 11, 2026 Pap smear results can be confusing or scary. Learn what normal and abnormal results mean, what affects cervical cancer risk, and when follow-up testing is needed. March 03, 2026 | Amy J. Ware, MHA, MEd, FACHE January 27, 2026 Lifestyle tips and changes people can take to improve their cervical health.
Sarah Cannon Research Institute to present research on Advances in blood cancers and blood disorders at 2025 ASH Annual Meeting & Exposition. December 3, 2025 | NASHVILLE, Tenn.-(BUSINESS WIRE)-Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today that it will showcase its latest research through 100 abstracts and presentations at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9. SCRI's expansive network is represented by more than 50 researchers who serve as first authors and co-authors across over 15 research locations. A comprehensive list of SCRI abstracts and presentations at this year's Annual Meeting & Exposition can be found here. "This year's ASH Annual Meeting & Exposition marks a milestone for SCRI, with the largest number of accepted abstracts and presentations in our history," said David Spigel, MD, Chief Scientific Officer, SCRI. "This achievement reflects not only the significance of the research, but also the meaningful collaboration and unwavering commitment of the investigators across our network, all united to advance the science that transforms care for people facing blood cancers and blood disorders." * Haydar Frangoul, MD, MS, SCRI at TriStar Centennial Children's Hospital, will present "First Results of Exagamglogene Autotemcel in Pediatric Patients Aged 5-11 Years with Transfusion-Dependent Β-Thalassemia or Sickle Cell Disease with Recurrent Severe Vaso-Occlusive Crises" in an oral presentation on Saturday, December 6 at 4:00 p.m. EST in OCCC - Chapin Theatre (W320). * Dr. Frangoul is also first author on an oral presentation titled, "Enhanced CD34+ Cell Mobilizations, Collections, and Comparable Safety Profile with Fixed Dose versus Weight-Based Plerixafor Dosing in Patients with Sickle Cell Disease Receiving Autologous CD34+ Base-Edited Hematopoietic Stem Cells in the Ongoing BEACON Study" on Monday, December 8 at 5:30 p.m. EST in Hyatt - Regency Ballroom R. * Nosha Farhadfar, MD, SCRI at Methodist Healthcare, is first author on an oral presentation alongside Stephen Strickland, MD, MSCI, SCRI, and Alireza Eghtedar, MD, SCRI at Colorado Blood Cancer Institute, titled, "Promising Results from an Ongoing Phase I Multicenter Study of Senti-202, a First-In-Class, CD33 and/or FLT3 & Not Endomucin, Selective Off-The-Shelf Logic Gated CAR NK Cell Therapy in Adults with Relapsed/Refractory Acute Myeloid Leukemia" on Monday, December 8 at 5:45 p.m. EST in OCCC - Valencia Room W415BC. * Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center I The US Oncology Network, serves as first author alongside co-authors John Burke, MD, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, and Shachar Peles, MD, SCRI at Florida Cancer Specialists & Research Institute I The US Oncology Network, on an oral presentation titled, "Fixed Treatment Duration Subcutaneous Mosunetuzumab Monotherapy in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Interim Results from The Phase II MorningSun Study" on Saturday, December 6 at 9:45 a.m. EST in OCCC - Tangerine Ballroom F2. * Dr. Burke is first author alongside co-author Dr. Sharman on an oral presentation titled, "Fixed-Duration Subcutaneous Mosunetuzumab, with Maintenance Therapy, in Patients with Previously Untreated High-Tumor Burden Follicular Lymphoma: Longer Follow-Up and Exploratory Circulating Tumor DNA Analysis of The Phase II MorningSun Study" on Saturday, December 6 at 3:15 p.m. EST in OCCC - Tangerine Ballroom F2. * James Essell, MD, SCRI at OHC I The US Oncology Network, is first author on an oral titled, "Remote Therapeutic Monitoring Reduces Hospitalization due to Infection in Patients Being Treated for Hematological Malignancy" on Saturday, December 6 at 10:30 a.m. EST in OCCC - W230. * Dr. Farhadfar will deliver "Safety and Feasibility of 0.6 mg/kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study" in an oral presentation on Saturday, December 6 at 2:15 p.m. EST in OCCC - W331. In addition to scientific presentations, SCRI researchers will participate in and lead ASH Annual Meeting & Exposition sessions, including: * Hans Lee, MD, SCRI, will moderate the session, Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma, on Saturday, December 6 at 2:00 p.m. EST in OCCC - West Hall D1. * Dr. Burke will present "Engagement of Community Physicians in Clinical Trials" during the session, How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care? on Sunday, December 7 at 9:40 a.m. EST in Hyatt - Plaza Int'l HIJK.
Bristol Myers Squibb expands its Strategic Collaboration with Sarah Cannon Research Institute. Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI's Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations. In an effort to accelerate the overall development of innovative cancer therapies and increase access to clinical trials for patients across the U.S., Bristol Myers Squibb and Sarah Cannon Research Institute (SCRI) announced an expansion to its strategic collaboration.[1] Through this expanded collaboration effort, SCRI and Bristol Myers Squibb will increase access to Bristol Myers Squibb's therapy solutions by embedding clinical trials in community settings, and with more than 1,300 physicians engaged in research spanning across more than 20 states, SCRI's network enables broader participation in clinical trials.[1] During the early phase of the collaboration, SCRI achieved a 45% reduction in study startup timelines spanning across eight Bristol Myers Squibb clinical trials, significantly outperforming timelines observed at non-SCRI sites.[1] These capabilities are expected to be scaled across SCRI's research network, reinforcing a shared commitment to transforming clinical trial delivery, while also ensuring an increase to patient access to the latest cancer treatments and innovations.[1] Why did Bristol Myers Squibb and Sarah Cannon Research Institute expand its collaboration? According to a press release, a key factor of the collaboration is SCRI's next-generation clinical trial delivery model Accelero, which streamlines operations and accelerates trial execution spanning SCRI's expansive network of upwards of 200 locations.[1] The expanded collaboration effort aims to align Bristol Myers Squibb's pioneering oncology pipeline with SCRI's research infrastructure and expertise, bringing cutting-edge research directly to patients where they live and receive care.[1] "Together, SCRI and Bristol Myers Squibb are translating innovative science into clinical trials and accelerating patient enrollment through SCRI's Accelero model that prioritizes speed, quality, and access, and ultimately brings promising therapies to patients faster and closer to home," said Dee Anna Smith, chief executive officer, SCRI. "We look forward to the impact we will have together as we reach more patients and continue to redefine how clinical trials are delivered across the country." Bristol Myers Squibb's statement on its expanded collaboration with SCRI. "At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment," said Mokash Sharma, Senior Vice President, Global Development Operations, Bristol Myers Squibb. "Improving access to clinical research isn't just about science - it's about trust, and meeting people where they are. By leveraging data-driven strategies through our collaboration with Sarah Cannon Research Institute, we're working to ensure that more patients - especially those from medically underserved populations - have access to vital cancer research advances in their communities. This partnership reflects our shared vision to transform clinical trial delivery and advance health equity across the oncology landscape." * Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research Bristol Myers Squibb November 12, 2025 Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Nashville, Tenn. [06.01.25] - SCRI Oncology Partners, a dedicated cancer treatment center led by globally recognized oncology experts, is proud to welcome Hans Lee, MD, and Cody Lebeck Lee, MD to the practice.
FORT MYERS, Fla., Nov. 22, 2024 /PRNewswire/ -- A landmark in cancer treatment has come full circle, as the U.S. Food and Drug Administration (FDA) approved revumenib, a revolutionary drug for relapsed or refractory acute leukemia with a KMT2A translocation on November 15, 2024. This life-saving therapy, first administered to a Florida Cancer Specialists Research Institute, LLC (FCS) patient at its Sarasota Drug Development Unit (DDU) in 2019 as part of a Phase 1 clinical trial, is now available to patients nationwide. The very first patient to ever receive this groundbreaking treatment was referred by FCS medical oncologist/hematologist Muhammad Imam, MD to FCS Director of Drug Development Manish R. Patel, MD at the FCS Sarasota DDU, one of three early-phase clinical trial sites within the statewide practice